Literature DB >> 8671902

Alteration of the lipid and apolipoprotein contents of lipoprotein (a) in haemodialysis patients.

V Hugue1, M Kandoussi, H J Parra, M Dracon, J C Fruchart, A Tacquet, C Cachera.   

Abstract

BACKGROUND: To examine the possible alteration in Lp(a) composition, protein and lipid contents of Lp(a) were determined in 10 haemodialysis patients (HD) matched with 10 controls (C) for apo(a) phenotypes.
METHODS: All subjects (HD and C) had Lp(a) concentrations greater than 30 mg/dl (mean+/-SD : 82.3+/-41.4 vs 49. 3+22.5 mg/dl), a concentration which has been determined to be associated with an elevated cardiovascular risk. Apo(a)-containing particles were isolated by immunoaffinity chromatography using a monoclonal anti-apo(a) antibody.
RESULTS: The molar concentrations of lipid and protein constituents of immunoaffinity isolated Lp(a) were expressed as number of moles per mole of apo(a). Lp(a) from HD patients were significantly richer in apo Cl11 (P<0.05) and triglycerides (TG) (P<0.05), compared to those of controls. Molar ratios of apo B, apo E, cholesterol and phospholipid s per apo(a)-containing particles were in the same range in both groups.
CONCLUSION: Lp(a) from HD patients is characterized by an elevated content in TH and apo Cl11 in comparison with those of controls. Further studies are needed to evaluate in HD patients the contribution of changes in Lp(a) composition towards the metabolism of these particles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671902     DOI: 10.1093/oxfordjournals.ndt.a027406

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  1 in total

1.  Cytotoxic effects exerted by polyarylsulfone dialyser membranes depend on different sterilization processes.

Authors:  Emna El Golli-Bennour; Bochra Kouidhi; Mouna Dey; Rabia Younes; Chayma Bouaziz; Chiraz Zaied; Hassen Bacha; Addellatif Achour
Journal:  Int Urol Nephrol       Date:  2009-10-01       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.